P/E Ratio

Fairplay's new user verification signals a market-wide shift. As India's stringent new rules take hold, compliance is becoming a key strategic asset.

MIT's Kristin Forbes argues rigid models are failing. She's adapting Sun Tzu's 'Art of War' to help central banks fight today's lightning-fast crises.

While others debate AI's future, CEO Eric Vaughan brings a radical playbook of M&A and cultural overhaul to the main stage, proving enterprise AI is here.

As The Conference Board honors S&P Global and UL Solutions, it’s clear that investing in people is no longer a soft skill—it's the core of modern strategy.

QuadReal's appointment of Deloitte veteran Trevor Nakka signals a strategic pivot, adding elite financial governance to its $98.5B portfolio to fuel a disciplined global expansion.

The maker of SUPERPRETZEL and ICEE maintains its shareholder payout, offering a competitive yield as it navigates market pressures and transformation.

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

FortuneX Acquisition Corp. raised $75M in its IPO, but it enters a SPAC market wary of past failures and facing stricter regulatory oversight.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

The U.S. Army's $49M NCODE pilot offers a lifeline to contractors, validating secure enclave solutions like Beryllium's Cuick Trac for CMMC compliance.

AUX AIR USA's new One-Way Cassette offers a sleek, powerful HVAC solution for modern homes and tight spaces where aesthetics are paramount.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

Newly public Yesway faces its first major test with its Q1 earnings. Investors will scrutinize if its aggressive expansion can meet high analyst expectations.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

As the space economy booms, a top TMT research firm launches dedicated coverage, signaling a new era of financial scrutiny for giants like SpaceX and Rocket Lab.

Despite strong earnings, LifeStance shares fall after a major investor sale. The company's own share repurchase signals a complex financial strategy.

Crane Company posts a robust Q1, powered by new acquisitions. The industrial giant raises its full-year guidance, signaling confidence amid economic headwinds.